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Analysis and control of human immunodeﬁciency virus (HIV) infection have attracted
the interests of mathematicians and control engineers during the recent years. Several
mathematical models exist and adequately explain the interaction of the HIV infection
and the immune system up to the stage of clinical latency, as well as viral suppression
and immune system recovery after treatment therapy. However, none of these models can
completely exhibit all that is observed clinically and account the full course of infection.
Besides model inaccuracies that HIV models suffer from, some disturbances/uncertainties
from different sources may arise in the modelling. In this paper we study the basic
properties of a 6-dimensional HIV model that describes the interaction of HIV with two
target cells, CD4+ T cells and macrophages. The disturbances are modelled in the HIV
model as additive bounded disturbances. Highly Active AntiRetroviral Therapy (HAART) is
used. The control input is deﬁned to be dependent on the drug dose and drug eﬃciency.
We developed treatment schedules for HIV infected patients by using robust multirate
Model Predictive Control (MPC)-based method. The MPC is constructed on the basis of the
approximate discrete-time model of the nominal model. We established a set of conditions,
which guarantee that the multirate MPC practically stabilizes the exact discrete-time model
with disturbances. The proposed method is applied to the stabilization of the uninfected
steady state of the HIV model. The results of simulations show that, after initiation of
HAART with a strong dosage, the viral load drops quickly and it can be kept under a
suitable level with mild dosage of HAART. Moreover, the immune system is recovered with
some ﬂuctuations due to the presence of disturbances.
© 2009 Elsevier Inc. All rights reserved.
1. Introduction
Over the last decade a tremendous effort has been made in developing mathematical models of the immunology dy-
namics under the attack of the human immunodeﬁciency virus (HIV) and under the inﬂuence of antiretroviral therapies.
HIV is responsible of acquired immunodeﬁciency syndrome (AIDS). HIV is a retrovirus which infects the CD4+ T cells and
macrophages which are the crucial immune responses and play important roles in phagocytosis. After infection, the CD4+ T
cells lose their function and become a virus factory, producing new virus particles until its death. Macrophages live longer
than the CD4+ T cell and it is an important source of virus after CD4+ T cell depletion. When the number of CD4+ T cell
reaches below 200 cell/mm3 of plasma, the HIV infected patient is regarded as an AIDS patient.
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categories of anti-HIV drugs are reverse transcriptase inhibitors (RTI) drugs and protease inhibitors (PI) drugs. Reverse
transcriptase inhibitors prevent the HIV from infecting cells by blocking the integration of the HIV viral code into the
host cell genome. Protease inhibitors prevent already infected host cells from producing infectious virus particles. Recently,
Highly Active AntiRetroviral Therapies (HAART) which consist of one or more RTI and a PI, can suppress viral load below
detectable levels and consequently prolong time to the onset of AIDS.
Optimal treatment scheduling of HIV infection using a control theoretic approach is the subject of substantial research
activity. In [13,24,28,9,23,1,27,38], open-loop type optimal controllers are designed using the Pontryagin’s Maximum Princi-
ple. A major drawback of open-loop optimal controllers is their lack of robustness against disturbances/model uncertainties.
In fact, HIV dynamics are poorly known, this leads to model inaccuracies and parameter uncertainties. Also, another source
of disturbances may arise from immune system ﬂuctuating or immune effect of a coinfection, in addition to the measure-
ments errors and estimation errors when using an observer to estimate the unmeasured states. Therefore, the design of
optimal treatment schedules based on open loop optimal controller, may lead to undesired results. To overcome this prob-
lem, we have to design a feedback controller, that inherits a certain robustness to disturbances. Feedback control for HIV
has been studied by [3,5,4].
In the last few years, model predictive control (MPC) method is developed for determining optimal treatment schedules
for HIV patients [37,11,12,39,20,17]. The MPC method obtains the feedback control by solving a ﬁnite horizon optimal
control problem at each time instant using the current state of the system as the initial state for the optimization and
applying “the ﬁrst part” of the optimal control. The study of stabilizing property of such schemes has been the subject of
intensive research in recent years (see e.g. [15,2,29]).
In [39], the MPC is constructed on the basis of the discrete-time model where the sampling period is chosen to be
seven days (i.e., τ = 7). However, the authors did not consider the effect of the discretization of the differential equations
on the stability analysis. Moreover, for large sampling periods, the viral load and the CD4+ T cell count could not be kept
within baseline ranges (see [25]). Alternatively, the optimal control problems can be solved by continuously varying drug
levels in [37]. However, continuous-time variation of the dose seems hard to apply in the clinical treatment of patients.
In [11] and [12], the HIV model is discretized with a suitable numerical method with short sampling period, and the MPC
is designed on the basis of the approximate discrete-time model. For short sampling period, MPC is hard to apply to HIV
model, because it requires the availability of blood measurements every sampling instants (iτ , i = 0,1, . . .). A possible
solution of this problem is to design a multirate version of MPC, where the measurements are needed every  samplings
(iτ, i = 0,1, . . .) (see [17] and [18]). In [37] and [39], it is shown only by simulation that the applied MPC have a certain
degree of robustness to measurements and modelling errors.
The aim of the present paper is to develop treatment schedules for HIV infected patients by using robust multirate MPC.
The disturbances are modelled in the HIV model as additive bounded disturbances. The construction of MPC is based on
the approximate discrete-time model of the nominal model. We have shown that under suitable conditions, the multirate
MPC practically stabilizes the exact discrete-time model with disturbances. These conditions have been veriﬁed for the HIV
model. The importance of approximate discrete-time design is supported by a series of counter-examples (see e.g. [31,30]
and [16]), which show that even for disturbance-free systems one can design a controller to stabilize the approximate
model, but the original model is destabilized by the same controller. In [39], the MPC method is applied to an HIV model
without verifying the stability conditions of the proposed method such as the asymptotic controllability of the system and
the delectability condition.
The model of HIV infection we will use in this paper, considers the infection process of the HIV with two target cells,
CD4+ T cells and macrophages, which is a 6-dimensional nonlinear ODEs model. The importance of considering such model
is due to the observation of Perleson el al., that after the rapid ﬁrst phase of decay during the initial 1–2 weeks of an-
tiretroviral treatment, plasma virus levels declined at a considerably slower rate [34]. This second phase of viral decay was
attributed to the turnover of a longer-lived virus reservoir of infected cell population. Therefore, the two target cells model
is more accurate than the one target cell model (see [35] and [7]). Models used in [37,11,12,39,17] do not capture the
detailed viral dynamics the occur in macrophages. In our paper, we studied the basic properties of the 6-dimensional HIV
model with additive disturbances. Note that these basic properties of the 6-dimensional HIV model are not well studied
in the literature, compared with those of, say, the 4-dimensional model [33], and they are important for understanding
the associated characteristics of the HIV dynamics. This also helps us to verify the stability conditions of the MPC method.
The simulation results show that after initiating the HAART, the viral load drops dramatically and it can be kept under a
suitable level by using a mild dosage of HAART. Moreover, the immune system returns near to the normal status with some
ﬂuctuations due to the presence of disturbances.
The layout of the paper is as follows: In Section 2, we introduce the HIV model and study its basic properties. In Sec-
tion 3, we outline the robust multirate MPC design for sampled-data nonlinear systems and summarize the main results
obtained in [16] and [10]. Application of robust MPC to the HIV model is given in Section 4. Section 5 presents the simula-
tion results. The last section is the conclusion.
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We shall use the mathematical model of HIV infection proposed by ([35] and [7]), incorporating to allow some distur-
bances. For simplicity we shall assume that the disturbances are model as additive which can model perturbed systems and
a wide class of model mismatches. This model describes two co-circulation populations of target cells, potentially repre-
senting CD4+ T cells and macrophages. The model can simulate differential drug penetration into target cell co-circulating
in plasma, see [19]. After initiation of HAART which consists of RTI and PI drugs the model can be written as:
T˙ = s1 − d1T − β1T V + w1, (1)
T˙1 = q1e−u1β1T V − k1T1 − μ1T1 + w2, (2)
T˙2 = q2e−u1β1T V + k1T1 − μ2T2 + w3, (3)
M˙ = s2 − d2M − β2MV + w4, (4)
M˙1 = qMe−u1β2MV − δM1 + w5, (5)
V˙ = e−u2 p1T2 + e−u2 p2M1 − cV + w6. (6)
The state variables describes the plasma concentrations of: T , the uninfected CD4+ T cells; T1, the latently infected CD4+ T
cells; T2, the actively infected CD4+ T cells; M , the uninfected macrophages; M1, the infected macrophages; and V , the free
virus particles.
The populations of the uninfected CD4+ T cells and macrophages are described by Eqs. (1) and (4), respectively, where
s1 and s2 represent, respectively, the rates of which new CD4+ T cell and macrophages are generated from sources within
the body, d1, d2 are the death rate constants, and β1, β2 are the infection rate constants. Here, the law of mass action was
used. Eq. (2) describes the population dynamics of the latently infected CD4+ T cells and shows that they convert to actively
produce virus with a rate constant k1 and μ1 is their death rate constant. Eq. (3), describes the population dynamics of the
actively infected CD4+ T cells and shows that they die with rate constant μ2. Constants q1 and q2 are the probabilities that
upon infection a CD4+ T cell become either latent or actively producing virus. In Eq. (5), qM is the probability of successfull
infection, δ is the death rate constant of the infected macrophages. The virus particles are produced by the actively infected
CD4+ T cells and infected macrophages with rate constants p1 and p2, respectively, and are cleared from plasma with rate
constant c. We emphasize that all the parameters of the model are positive and they differ from one patient to another.
For the estimation of HIV model parameters, we refer the reader to the following papers [40,41,22,42]. The effect of the RTI
and PI drugs are represented by the chemotherapy functions e−ψ1m1(t) and e−ψ2m2(t) where ψ1 and ψ2 are the eﬃciencies
of RTI and PI drugs, respectively, and m1(t) and m2(t) are the drug dose at time t (see [6]). We shall consider the control
input as ui(t) = ψimi(t), i = 1,2.
In Eqs. (1)–(6), wi(t) describes model uncertainties/disturbances that may arise from different sources such as, modelling
errors, immune system ﬂuctuation, immune effect of a co-infection, measurement noise, estimation errors, and so on.
We assume that, the model uncertainties/disturbances satisfy the following bound∥∥wi(t)∥∥ i, i  0, i = 1, . . . ,6. (7)
We are now ready to present a study on the basic mathematical properties of the model.
2.1. Positive invariance
Now we show that the model (1)–(6) is biologically acceptable in the sense that no population goes negative. To do so,
we show that under which conditions the nonnegative orthant R6+ is positively invariant for (1)–(6):
T˙ |(T=0) = s1 + w1  0 if w1 −s1,
T˙1|(T1=0) = q1e−u1β1T V + w2  0 if w2 −q1e−u1β1T V ,
T˙2|(T2=0) = q2e−u1β1T V + k1T1 + w3  0 if w3 −q2e−u1β1T V − k1T1,
M˙|(M=0) = s2 + w4  0 if w4 −s2,
M˙1|(M1=0) = qMe−u1β2MV + w5  0 if w5 −qMβ2e−u1MV ,
V˙ |(V=0) = e−u2 p1T2 + e−u2 p2M1 + w6  0 if w6 −e−u2 p1T2 − e−u2 p2M1, (8)
with (T , T1, T2,M,M1, V ) 0. This means that under the above conditions the nonnegative orthant R6+ is positively invari-
ant, namely, if a trajectory starts in the nonnegative orthant, it remains there. We note that, the conditions in (8) give a
lower bound of the disturbances only at the boundary of R6+ .
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exists such positive numbers L1 , L2 and L3 that the compact set
Ω = {(T , T1, T2,M,M1, V ): 0 T , T1, T2  L1, 0 M,M1  L2, 0 V  L3}, (9)
is positively invariant.
Proof. Let Ttot = T + T1 + T2, and Mtot = M + M1. Then
T˙ tot =
(
e−u1q1 + e−u1q2 − 1
)
β1T V + s1 + w1 + w2 + w3 − d1T − μ1T1 − μ2T2
 (q1 + q2 − 1)β1T V + s1 + w1 + w2 + w3 − d1T − μ1T1 − μ2T2
 s1 + 1 + 2 + 3 − σ1Ttot,
M˙tot =
(
e−u1qM − 1
)
β2MV + s2 + w4 + w5 − d2M − δM1
 (qM − 1)β2MV + s2 + w4 + w5 − d2M − δM1
 s2 + 4 + 5 − σ2Mtot,
where σ1 = min{d1,μ1,μ2} and σ2 = min{d2, δ}. Hence 0 Ttot(t) s1+1+2+3σ1 for all t  0 if Ttot(0)
s1+1+2+3
σ1
, and
0 Mtot(t) s2+4+5σ2 for all t  0 if Mtot(0)
s2+4+5
σ2
. It follows that 0 T (t), T1(t), T2(t) L1 and 0 M(t),M1(t) L2
for all t  0 if T (0), T1(0), T2(0) L1, and M(0),M1(0) L2, where L1 = s1+1+2+3σ1 and L2 =
s2+4+5
σ2
. On the other hand,
V˙ (t) e−u2 p1L1 + e−u2 p2L2 − cV + w6  p1L1 + p2L2 − cV + 6,
then 0 V (t) L3 for all t  0, if V (0) L3, where L3 = p1L1+p2L2+6c . 
Note that Ω contains all the biologically relevant states, thus we can restrict the state space of the system to the compact
set Ω . Since the drug doses cannot be arbitrarily increased we may consider a compact control constraint set only.
2.2. Steady states
We shall compute the steady states of system (1)–(6) under constant controller in the absence of the disturbances, i.e.,
for u j(t) = u j , j = 1,2, and wi(t) = 0, i = 1,2, . . . ,6, t  0. A steady state (T , T1, T2,M,M1, V ) satisﬁes
s1 − d1T − β1T V = 0, (10)
q1e
−u1β1T V − k1T1 − μ1T1 = 0, (11)
q2e
−u1β1T V + k1T1 − μ2T2 = 0, (12)
s2 − d2M − β2MV = 0, (13)
qMe
−u1β2MV − δM1 = 0, (14)
e−u2 p1T2 + e−u2 p2M1 − cV = 0. (15)
Solving T1, T2 and M1 from equations (11), (12) and (14) in terms of T V and/or MV and inserting them into (15) we
obtain
(a4T + a5M − c)V = 0, (16)
where
a4 = p1β1[k1q1 + (k1 + μ1)q2]e
−(u1+u2)
μ2(k1 + μ1) , a5 =
p2β2qMe−(u1+u2)
δ
.
The ﬁrst solution of (16) is V = 0. Then substituting it in (10)–(14), we obtain the uninfected steady state E0 =
(T0,0,0,M0,0,0) where T0 = s1d1 , M0 =
s2
d2
. If V = 0, then
a4T + a5M − c = 0, (17)
and by eliminating V from Eqs. (10) and (13) we obtain
a3T − a2TM − a1M = 0, (18)
where
a1 = s1β2, a2 = β1d2 − β2d1, a3 = s2β1.
We note that the coeﬃcients a1, a3, a4 and a5 are positive, while a2 may be positive, or negative, or equal zero.
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T ∗0 =
a1c
a1a4 + a3a5 , M
∗
0 =
a3c
a1a4 + a3a5 .
If a2 = 0, there are two possible solutions for (17) and (18)
T ∗+ =
−(a1a4 + a3a5 − a2c) +
√
(a1a4 + a3a5 − a2c)2 + 4a1a2a4c
2a2a4
,
M∗+ =
1
a5
(
c − a4T ∗+
)
,
T ∗− =
−(a1a4 + a3a5 − a2c) −
√
(a1a4 + a3a5 − a2c)2 + 4a1a2a4c
2a2a4
,
M∗− =
1
a5
(
c − a4T ∗−
)
.
Now we have to determine the positive solutions. First, we show that the discriminate 
 = (a1a4 + a3a5 − a2c)2 + 4a1a2a4c,
is positive
if a2 > 0, 
 = (a1a4 + a3a5 − a2c)2 + 4a1a2a4c > 0,
if a2 < 0, 
 = (a1a4 + a3a5 + a2c)2 − 4a2a3a5c > 0,
it follows that if a2 > 0 then
T ∗+ =
−(a1a4 + a3a5 − a2c) +
√
(a1a4 + a3a5 − a2c)2 + 4a1a2a4c
2a2a4
> 0,
and if a2 < 0, let a2 = −a2 and then
T ∗+ =
(a1a4 + a3a5 + a2c) −
√
(a1a4 + a3a5 + a2c)2 − 4a1a2a4c
2a2a4
> 0.
Similarly, it is easy to see that
a2 > 0 ⇒ T ∗+ > 0, and M∗+ > 0,
a2 < 0 ⇒ T ∗+ > 0, and M∗+ > 0,
a2 > 0 ⇒ T ∗− < 0, and M∗− > 0,
a2 < 0 ⇒ T ∗− > 0, and M∗− < 0.
Then, the only positive solutions are T ∗ = T ∗+ and M∗ = M∗+. Substituting them in Eqs. (10)–(14), we obtain the infected
steady state which is given by E1 = (T ∗, T ∗1 , T ∗2 ,M∗,M∗1, V ∗) where
T ∗ =
{
T ∗0 , if a2 = 0,
T ∗+, if a2 = 0, M
∗ =
{
M∗0, if a2 = 0,
M∗+, if a2 = 0,
T ∗1 =
q1e−u1d1
k1 + μ1
(
T0
T ∗
− 1
)
T ∗, T ∗2 =
e−u1qd1
μ2(k1 + μ1)
(
T0
T ∗
− 1
)
T ∗,
M∗1 =
qMe−u1d2
δ
(
M0
M∗
− 1
)
M∗, V ∗ = d1
β1
(
T0
T ∗
− 1
)
, (19)
where, q = k1q1 + (k1 + μ1)q2.
Let us deﬁne
Rc0(u1,u2) =
{p1β1T0δq + p2qMβ2M0(k1 + μ1)μ2}e−(u1+u2)
cδ(k1 + μ1)μ2 .
Lemma 1. The infected steady state E1 exists if and only if Rc > 1.0
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of E1, i.e., T ∗1 , T ∗2 ,M∗1, V ∗, are positive.
We can see that T ∗ and M∗ can be written as follows
T ∗ = A1
Rc0
− B1 +
√(
B1 − A1
Rc0
)2
+ 2a1A1
a2Rc0
, if a2 > 0, (20)
T ∗ = A1
Rc0
+ B1 −
√(
B1 + A1
Rc0
)2
− 2a1A1
a2Rc0
, if a2 < 0, (21)
T ∗ = T0
Rc0
, if a2 = 0, (22)
M∗ = A2
Rc0
+ B2 −
√(
B2 + A2
Rc0
)2
− 2a3A2
a2Rc0
, if a2 > 0, (23)
M∗ = A2
Rc0
− B2 +
√(
B2 − A2
Rc0
)2
+ 2a3A2
a2Rc0
, if a2 < 0, (24)
M∗ = M0
Rc0
, if a2 = 0, (25)
where, a2 = −a2, B1 = −B1, B2 = −B2 and
A1 = 1
2
T0 + p2qMβ2M0(k1 + μ1)μ2
2p1β1δq
, B1 = β2
2a2
[
T0d1 + p2qMM0d2(k1 + μ1)μ2
p1δq
]
,
A2 = 1
2
M0 + p1T0β1δq
2p2β2qM(k1 + μ1)μ2 , B2 =
β1
2a2
[
M0d2 + p1T0d1δq
p2qMμ2(k1 + μ1)
]
.
From Eqs. (20)–(25), it can be seen that T ∗ and M∗ are decreasing functions of Rc0.
Now we show that if Rc0 = 1 then T ∗ = T0 and M∗ = M0. Eqs. (20), (21), (23) and (24) can be simpliﬁed to the following
T ∗ = A1 − B1 +
√(
T0β1d2
2a2
+ β
2
2d1M0p2qM(k1 + μ1)μ2
2a2β1p1δq
)2
= A1 − B1 +
√
(B1 + T0 − A1)2 = T0, a2 > 0,
T ∗ = A1 + B1 −
√(
T0β1d2
2a2
+ β
2
2d1M0p2qM(k1 + μ1)μ2
2a2β1p1δq
)2
= A1 + B1 −
√
(A1 + B1 − T0)2 = T0, a2 < 0,
M∗ = A2 + B2 −
√(
M0β2d1
2a2
+ β
2
1d2T0p1δq
2a2β2p2qMμ2(k1 + μ1)
)2
= A2 + B2 −
√
(A2 + B2 − M0)2 = M0, a2 > 0,
M∗ = A2 − B2 +
√(
M0β2d1
2a2
+ β
2
1d2T0p1δq
2a2β2p2qMμ2(k1 + μ1)
)2
= A2 − B2 +
√
(B2 − A2 + M0)2 = M0, a2 < 0.
From the above analysis we obtain the following:
Rc0 = 1 ⇒ E1 = E0,
Rc0 > 1 ⇒ 0 < T ∗ < T0, 0 < M∗ < M0, and T ∗1 , T ∗2 ,M∗1, V ∗ > 0,
Rc0 < 1 ⇒ T ∗ > T0, M∗ > M0, and T ∗1 , T ∗2 ,M∗1, V ∗ < 0.
Now assume that the steady state E1 exists then T ∗1 , T ∗2 ,M∗1, V ∗ > 0, and from (19) we obtain T ∗ < T0, and M∗ < M0. It
follows from (17) that Rc0 > 1. 
2.3. Local stability of E0
Proposition 2. If Rc < 1, then E0 is locally asymptotically stable for the nominal system.0
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J =
⎡⎢⎢⎢⎢⎢⎢⎢⎣
−d1 0 0 0 0 −T0β1
0 −k1 − μ1 0 0 0 q1e−u1 T0β1
0 k1 −μ2 0 0 q2e−u1 T0β1
0 0 0 −d2 0 −M0β2
0 0 0 0 −δ qMe−u1M0β2
0 0 p1e−u2 0 p2e−u2 −c
⎤⎥⎥⎥⎥⎥⎥⎥⎦
.
The characteristic equation is given by:
Det( J − λI) = (λ + d1)(λ + d2)
[
λ4 + b3λ3 + b2λ2 + b1λ + b0
]= 0,
where
b0 = −
{
p1β1T0δq + p2qMβ2M0(k1 + μ1)μ2
}
e(−u1−u2) + cδ(k1 + μ1)μ2 = cδ(k1 + μ1)μ2
(
1− Rc0
)
,
b1 = −
{
p1β1T0(q + δq2) + p2qMβ2M0(k1 + μ1 + μ2)
}
e(−u1−u2) + cδ(μ1 + μ2 + k1) + μ2(c + δ)(μ1 + k1),
b2 = −{p1T0q2β1 + p2qMβ2M0}e(−u1−u2) + δ(μ1 + k1) + μ2(δ + μ1 + k1) + c(μ1 + μ2 + δ + k1),
b3 = c + μ1 + μ2 + δ + k1.
We note that b1 and b3 are positive, then by using the condition Rc0 < 1 we can show the following:
b1 > μ2δ(μ1 + k1) > 0,
b2 > δ(μ1 + k1) + μ2(δ + μ1 + k1) + c(μ1 + k1) > 0.
Moreover, the Routh–Hurwitz criteria hold. Then, E0 is locally asymptotically stable. 
Remark 1. For the parameters given in Table 1, we can see that, when there is no treatment, Rc0|(u1=u2=0) = 2.46493, then
E0 is unstable. In contrast, when we linearized the nominal model around the infected steady state E1, we found that all
eigenvalues of the jacobian matrix have a negative real part, this means that E1 is locally asymptotically stable.
2.4. Global stability of E0
Proposition 3. If Rc0(u1,u2) 1, then E0 is globally asymptotically stable for the nominal system.
Proof. By the method of Korobeinikov [26], we deﬁne a Lyapunov function for the nominal system
W (T , T1, T2,M,M1, V ) = γ1T0
[
T
T0
− ln
(
T
T0
)
− 1
]
+ γ2M0
[
M
M0
− ln
(
M
M0
)
− 1
]
+ γ3T1 + γ4T2 + γ5M1 + γ6V
with
γ1 = e−u1−u2 p1δq, γ2 = e−u1−u2 p2qMμ2(k1 + μ1),
γ3 = e−u2 p1k1δ, γ4 = e−u2 p1δ(k1 + μ1),
γ5 = e−u2 p2μ2(k1 + μ1), γ6 = μ2δ(k1 + μ1).
We note that W is deﬁned, continuous and positive deﬁnite for all (T , T1, T2,M,M1, V ) > 0. Also, the global minimum
W = 0 occurs at the uninfected steady state E0. Further, it satisﬁes
dW
dt
= s1γ1
[
2− T
T0
− T0
T
]
+ s2γ2
[
2− M
M0
− M0
M
]
+ γ6c
[
Rc0 − 1
]
V . (26)
Since the arithmetical mean is greater than or equal to the geometrical mean, then the ﬁrst two terms of (26) are less than
or equal to zero. Therefore, if Rc  1 then dW  0 for all T ,M, V > 0. 0 dt
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c
T and R
c
M
Rc0 = RcT + RcM ,
RcT =
p1β1s1qe−(u1+u2)
cd1(k1 + μ1)μ2 ,
RcM =
p2qMβ2s2e−(u1+u2)
cδd2
.
We observe that RcT and R
c
M are the basic reproduction ratio of each T-cell and macrophages dynamics separately. If R
c
0 < 1
then it is sure that RcT < 1 and R
c
M < 1. But if one considers only the four-dimensional model (10)–(12) and (15) and
designs a controller such that RcT < 1, then the whole system may be unstable around E0, because R
c
0 > 1. This shows the
importance of considering the effect of the macrophages in the HIV dynamics.
Proposition 4. The nominal system (1)–(6) is globally asymptotically controllable to E0 with piecewise constant controllers.
Proof. Let u1(t) = û1 and u2(t) = û2 with û1 + û2 > uc , where
uc = ln
(
p1β1T0δq + p2qMβ2M0(k1 + μ1)μ2
cδ(k1 + μ1)μ2
)
.
Then Rc0 (̂u1, û2) < 1, therefore the corresponding trajectory will tend to E0 as t → ∞. 
Remark 2. We observe that uc is the minimum controller required to obtain a treatment steady state viral load of zero.
Also, by solving the equation for V ∗ , the minimum drug dose that is required to obtain a treatment steady state viral load
below a speciﬁc value V sup (e.g. V sup = 50 copies mL−1) is given by
û1 + û2 > usup = ln
(
p1β1T0qd1
cμ2(d1 + V supβ1)(k1 + μ1) +
p2qMβ2M0d2
δc(d2 + V supβ2)
)
.
Remark 3. If one does not take into account the effect of macrophages cells, then our stability results are also useful for the
four-dimensional model T , T1, T2 and V , by putting s2 = d2 = β2 = δ = p2 = 0 (see [33]).
3. Robust multirate MPC for sampled-data systems
In this section, we outline the multirate MPC design for sampled-data nonlinear systems in the presence of bounded
disturbances and give a review on the results obtained in [16] and [10]. We have shown in the preceding section that, the
HIV system states can be taken from a compact set. Moreover, since the drug dosage of HAART cannot arbitrarily increased,
thus the controller can also be taken from a compact set. Therefore, we give only a short outline of the proof of the main
results of [10], when both the state space of the system and the control constraint set are restricted to compact sets.
The set of real and natural numbers (including zero) are denoted, respectively, by R and N. The notation R0 denote
the set of real numbers in the interval [0,∞). A continuous function σ : R0 → R0 is of class-K if σ(0) = 0, σ(s) > 0 for
all s > 0 and it is strictly increasing. It is of class-K∞ if it is of class-K and σ(s) → ∞ when s → ∞. A continuous function
β : R0 × R0 → R0 is of class-KL if β(s, τ ) is of class-K in s for every τ  0, it is strictly decreasing in τ for every
s > 0 and β(s, τ ) → 0 when τ → ∞. In what follows, the notation B
 = {z ∈ Rl: ‖z‖
} will be used in Rn.
Consider a continuous-time nonlinear control system with additive disturbances given by
z˙(t) = f (z(t),u(t))+ w(t), z(0) = z0 (27)
where z(t) ∈ Rn , u(t) ∈ U ⊂ Rm , w(t) ∈ W ⊂ Rp are the state, control input and disturbances, respectively, f : Rn × U → Rn
is continuous and Lipschitz continuous w.r.t z in any compact set and f (0,0) = 0, U is compact and 0 ∈ U , W is compact
and 0 ∈ W .
The control is taken to be a piecewise constant signal
u(t) = u(iτ ) =: ui, for t ∈
[
iτ , (i + 1)τ ), i ∈ N,
where τ > 0 is the control sampling period which is ﬁxed.
In this paper we address the problem of state feedback stabilization of (27) under “low measurement rate”. More pre-
cisely, we shall assume that state measurements can be performed at the time instants jτm , j = 0,1, . . . :
y j := z
(
jτm
)
, j = 0,1, . . . ,
where τm is the measurement sampling period. We assume that τm = τ for the integer  > 0 which is ﬁxed.
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denote the norm ‖w‖∞ := ess. sups0 ‖w(s)‖. We assume that there exists μ > 0 such that W ⊂ Bμ . Let us deﬁne
Wμ =
{
w ∈ L∞[0,∞): w(t) ∈ W a.e. t ∈ [0,∞) with ‖w‖∞ μ
}
,
Wρ =
{
w(i) = {wτ [i], . . . ,wτ [(i + 1) − 1]}, w ∈ Wρ, i = 0,1, . . .}.
We shall assume that there is a compact set X ⊂ Rn containing the origin, that is positively invariant with respect to
system (27) for any w(.) ∈ W and any piecewise constant controller u ∈ U . Let t → Φ E (t, z,u,w(.)) denote the solution
of (27) with given u, w and z = z(0). Then the exact discrete-time model can be deﬁned as
zi+1 = F˜ Eτ
(
zi,ui,wτ [i]
)
, (28)
where F˜ Eτ (z,u,wτ ) := Φ E (τ ; z,u,wτ ).
Let u(i) = {u(i)0 , . . . ,u(i)−1}, w(i) = {wτ [i], . . . ,wτ [(i + 1) − 1]} and F E (ξ,u,w) := Φ E (τ, ξ,u,w), then the exact -step
discrete-time model is given by
ξ Ei+1 = F E
(
ξ Ei ,u
(i),w(i)
)
, ξ E0 = z0. (29)
We note that the exact discrete-time models (28) and (29) describe, respectively, the behavior of the system at the time
instants kτ and kτ , k = 0,1, . . . .
In this work, the construction of multirate MPC is based on the nominal prediction and only small disturbances are
allowed. The nominal system of (27) is given by
x˙(t) = f (x(t),u(t)), x(0) = z(0), (30)
and its exact discrete-time model is given by
xEi+1 = F Eτ
(
xEi ,ui
)
. (31)
We note that, since f is typically nonlinear, F Eτ in (31) is not known in most cases, therefore the controller design can be
carried out by means of the nominal approximate discrete-time model
xAi+1 = F Aτ ,h
(
xAi ,ui
)
, (32)
where h is a modelling parameter, which is typically the step size of the underlying numerical method. The applied numer-
ical scheme approximation has to ensure the closeness of the exact models in the following sense.
Assumption A1. There exists an h∗ > 0 such that
(i) F Aτ ,h(0,0) = 0, F Aτ ,h is continuous in both variables uniformly in h ∈ (0,h∗], and Lipschitz continuous w.r.t x in any
compact set, uniformly in small h,
(ii) there exists a γ ∈ K such that∥∥F Eτ (x,u) − F Aτ ,h(x,u)∥∥ τγ (h)
for all x ∈ X , all u ∈ U , and h ∈ (0,h∗].
Assumption A2. There exists an h∗ > 0 such that the nominal exact discrete-time model (31) is practically asymptotically
controllable from X to the origin with piecewise constant controllers for all h ∈ (0,h∗]. (See e.g. [16] for the deﬁnition.)
For the solutions of (28), (31) and (32) with u = {u0,u1, . . .}, w = {wτ [0],wτ [1], . . .} and x0 we shall use the notations
Φ Ei (x0,u,w), φ
E
i (x0,u) and φ
A
i (x0,u), respectively.
The following problem is to be solved: for given τ and  ﬁnd a control strategy
vh : X → U × U × · · · × U︸ ︷︷ ︸
 times
, vh(x) =
{
u0(x), . . . ,u−1(x)
}
,
using the nominal approximate discrete-time model (32), to practically stabilize the exact discrete-time system (28).
Let N ∈ N with N   be given. Let (32) be subject to the cost function
Jτ ,h(N, x,u) =
N−1∑
i=0
τ lh
(
xAi ,ui
)+ g(xAN), (33)
where u= {u0, . . . ,uN−1}, xA = φA(x,u), i = 0,1, . . . ,N , lh and g are given functions, satisfying the following assumptions.i i
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(i) g : X1 → R is continuous, positive deﬁnite radially unbounded and Lipschitz continuous in any compact set,
(ii) lh(x,u) is continuous with respect to x and u, uniformly in small h, and Lipschitz continuous in any compact set,
(iii) there exist an h∗ > 0 and two class-K∞ functions ϕ1 and ϕ2 such that the inequality
ϕ1
(‖x‖) lh(x,u) ϕ2(‖x‖)+ ϕ2(‖u‖),
holds for all x ∈ X1, u ∈ U and h ∈ (0,h∗].
Assumption A4. There exist h∗ > 0 and η > 0 such that for all x ∈ Gη = {x: g(x)  η} there exists a κ(x) ∈ U such that
inequality
τ lh
(
x, κ(x)
)+ g(F Aτ ,h(x, κ(x))) g(x) (34)
holds true for all h ∈ (0,h∗].
We deﬁne the value function, which represents the optimal value of (33) for a given initial condition, as
VN(x) = inf
{
Jτ ,h(N, x,u): ui ∈ U
}
.
If this optimization problem has a solution denoted by u∗ = {u∗0, . . . ,u∗N−1}, then the ﬁrst  elements of u∗ are applied
at the state x, i.e.,
vh(x) =
{
u∗0(x), . . . ,u∗−1(x)
}
.
Let h∗0 denote the minimum of the values h∗ generated by Assumptions A1–A4. Let 
x and 
u be such numbers that‖x‖
x , ‖u‖
u if x ∈ X , u ∈ U .
Theorem 1. (See [16].) If Assumptions A1–A4 hold true, then
(i) there exist an h∗1 with 0< h∗1  h∗0 , and a constant V Amax independent of N, such that VN(x) V Amax for all x ∈ X , h ∈ (0,h∗1] and
N ∈ N,
(ii) there exist constants N∗ , LV and δV and functions σ1, σ2 ∈ K∞ such that for all x ∈ X , N > N∗ , h ∈ (0,h∗1] and i = 1,2, . . . , ,
σ1
(‖x‖) VN(x) σ2(‖x‖),
VN
(
φAi
(
x,vh(x)
))− VN(x)−τϕ1(‖x‖).
Moreover, for all x, y ∈ X1 with ‖x− y‖ δV ,∣∣VN(x) − VN(y)∣∣ LV ‖x− y‖
for all h ∈ (0,h∗1].
Clearly X ⊂ {x: VN(x) V Amax}.
Theorem 2. Suppose that Assumptions A1–A4 are valid and N is chosen such that N  N∗ . Then, there exist β ∈ KL, θ ∈ K∞ ,μ∗ > 0
and for any δ > 0 there exists an h∗ > 0 such that for any x0 ∈ X , and h ∈ (0,h∗] the trajectory of the -step exact discrete-time
system
ξ Ei+1 = F E
(
ξ Ei ,vh
(
ξ Ei
)
,w(i)
)
, ξ E0 = x0, (35)
with the -step MPC vh and w(i) ∈ Wμ
∗
 satisﬁes∥∥ξ Ei ∥∥ β(‖x0‖, iτ )+ θ(μ∗)+ δ for all i  0.
Proof. The proof can follow the same line as that of Theorem 2 in [10] and Theorem III.1 in [32] with small modiﬁcations
due to the global character of the statement (in the sense that the whole state space X belongs to the basin of attraction).
Moreover, because of our assumptions of the positive invariance of X , we know that ξ Ek ∈ X , if ξ E0 = x0 ∈ X . Thus, we give
only a short outline of the proof. Let L f > 0 be the Lipschitz constant of f . Using Assumption A1 and Gronwall’s lemma,
we can show that, there exists an h∗2 > 0 such that∥∥Φ E(x0,vh(x0),w(0))− φA(x0,vh(x0))∥∥ γ (h) + Lμ, i = 0,1, . . . , i i
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L f τ−1
eL f τ −1 and L = τe
L f τ e
L f τ−1
eL f τ −1 . Let ν > 0 be an arbi-
trary number. Let σ1 and σ2 be given in Theorem 1 and let δ1 = σ−12 ( ν4 ) and L̂ = 2LLV . Let h∗3 > 0 and μ1 be such that
inequalities
γ (h) < min
{
ν
4LV
,
τ
4LV
ϕ1(δ1),
1
4
δV
}
, μ1 < min
{
τ
L̂
ϕ1(δ1),
3
4L
δV
}
hold true for all h ∈ (0,h∗3]. Let h∗ = min{h∗2,h∗3} and μ∗ = min{μ,μ1} and choose d = L̂μ∗ + ν . Using Theorem 1 and the
deﬁnition of d, one can show in the same way as in [10] that if ξ Ek ∈ X and either VN (ξ Ek+1) d2 or VN (ξ Ek ) d hold true,
then
VN
(
ξ Ek+1
)− VN(ξ Ek )−τ4ϕ1(∥∥ξ Ek ∥∥). (36)
The construction of a suitable KL function is standard (see e.g. [31]). 
Remark 4. We note that it is not easy to calculate the maximum integration step size h∗ as well as the maximum distur-
bance bound μ∗ given in Theorem 2. Nevertheless, the result is of value, since it underpins that small integration step size
and small additive disturbances can be tolerated.
4. Robust MPC for the HIV model
In this section we apply the robust multirate MPC method proposed in section 3 to the HIV model. We shall show that,
with a suitable choice of N and functions g and lh , the assumptions of the previous section can be satisﬁed. Introduce new
variables by the deﬁnition z1 = T − T0, z2 = T1, z3 = T2, z4 = M − M0, z5 = M1, z6 = V . In these new variables the model
(1)–(6) takes the form of (27) with
f (z,u) =
⎛⎜⎜⎜⎜⎜⎜⎜⎝
s1 − d1(z1 + T0) − β1(z1 + T0)z6
q1e−u1β1(z1 + T0)z6 − k1z2 − μ1z2
q2e−u1β1(z1 + T0)z6 + k1z2 − μ2z3
s2 − d2(z4 + M0) − β2(z4 + M0)z6
qMβ2e−u1(z4 + M0)z6 − δz5
e−u2 p1z3 + e−u2 p2z5 − cz6
⎞⎟⎟⎟⎟⎟⎟⎟⎠
, (37)
and w = (w1,w2,w3,w4,w5,w6)′.
Let the compact set X be deﬁned as
X = {z ∈ R6: −T0  z1  L1 − T0, 0 z2, z3  L1, −M0  z4  L2 − M0, 0 z5  L2, 0 z6  L3},
where L1, L2 and L3 are as in Proposition 1.
With this deﬁnition, f satisﬁes all regularity assumptions, and according to Proposition 1, X is positively invariant if
q1 +q2  1 and qM  1. In what follows, we assume that q1 +q2  1 and qM  1. Since the drug doses cannot be arbitrarily
increased we can consider a compact control constraint set. The disturbance vector w is assumed to be bounded in a
compact set containing the origin.
We note that, when applying the receding horizon algorithm, the cost function Jτ ,h is redeﬁned at each sampling in-
stant, thus the applied control doesn’t minimize it over any interval. The optimization of this cost is not the aim of the
computations but it serves only as an aid for ﬁnding the desired stabilizing controller. Therefore the biological content
doesn’t play any role in its choice. Caetano and Yoneyama [6] proposed a cost function which has a biological meaning, but
it is not suitable for our MPC approach. In the receding horizon control literature, there are several strategies for choosing
the design parameters to satisfy stability conditions (see [8,14] and [18]). We call design parameters the data present in the
open-loop optimal control problem that we are able to choose; these are the control horizon N , the running and terminal
costs functions lh and g and the terminal set Gη . In what follows we show that under appropriate choice of the design
parameters, the stability conditions can be veriﬁed.
To verify Assumptions A3 and A4, we linearized the nominal system (37) around the origin in case of constant controllers,
i.e., u1(t) = u1 > u(1)c , u2(t) = u2 > u(2)c with u(1)c + u(2)c = uc , where uc is given in Proposition 4. Let AC be the coeﬃcient
matrix of the linearized system and x = (T − T0, T1, T2,M − M0,M1, V )′ . Then the discrete-time model for the linearized
system is given by:
x(k + 1) = eAC τ x(k). (38)
Let the sampling period be chosen to be τ = 1 and, u1 = u2 = 2. The running cost and the terminal cost can be chosen
as:
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The values of the parameters in the HIV model and the system states at the initiation of the therapy.
Parameter Value Variable Value
s1 104 mL−1day−1 T 4.0385× 105 mL−1
d1 0.01 day−1 T 1 8.5× 102 mL−1
β1 4.5× 10−8 mL day−1 T 2 6.6× 103 mL−1
q1 0.005 M 1.398× 104 mL−1
q2 0.55 M1 1.61× 103 mL−1
μ1 0.01 day−1 V 3.2798× 105 mL−1
k1 0.025 day−1
μ2 0.5 day−1
p1 240 cell−1day−1
c 5 day−1
β2 1.75× 10−8 mL day−1
δ 0.05 day−1
p2 35 cell−1day−1
qM 1
s2 150 mL−1day−1
d2 0.005 day−1
lh(x,u) = α1x′Q x+ α2
(
u1 − u(1)c
)2 + α3(u2 − u(2)c )2, (39)
g(x) = x′Px, (40)
where αi are positive weighting constants, P is a positive deﬁnite diagonal matrix and Q is a positive deﬁnite symmetric
matrix satisfying the Lyapunov equation for the discrete-time system (38)
Q = −(A′τ P Aτ − P), Aτ = eAC τ .
From (39)–(40), Assumption A3 is satisﬁed. Assumption A2 follows from Proposition 4 and Assumption A1 holds also true
if we choose a suitable numerical integration scheme (e.g. the Runge–Kutta formula). To verify Assumption A4, the weights
αi and the matrix P have been chosen through a series of numerical experiments as α1 = 0.01, α2 = 1000, α3 = 2000 and
P = diag(0.001,1,1,0.01,0.1,0.001). It has been veriﬁed numerically by solving a constrained minimization problem with
several starting points that Assumption A4 is satisﬁed over the whole set X . Thus all Assumptions of the proposed method
can be satisﬁed with suitable choice of the parameters of the MPC method. We note that by adjusting the weights αi as
well as the matix P , the performance of the MPC can be ﬁne-tuned. Similar case has been discussed in [39], therefore it
will not be presented in our paper.
5. Numerical results
We perform simulation studies using the parameter values taken from [24,36,7,3]. These values are listed in Table 1.
According to the suggestion in [21], we assume that the system is in the infected steady state before initiating the
treatment i.e. E1|(u1=u2=0) = (T , T 1, T 2,M,M1, V ), see Table 1.
We assume that the state measurements are performed at the instants jτ , j = 0,1, . . . . All computations are carried
out by MATLAB. In particular, the optimal control sequence is computed by the fmincon code of the Optimization toolbox.
To reduce the computational complexity we chose horizon length N to be N = 8 and  = 4. The disturbances are simulated
by wi(t) ∈ [ηi, i],
wi(t) = wi( j) = ηi + (i − ηi)r( j), t ∈
[
jτ , ( j + 1)τ ), i = 1, . . . ,6, j = 0,1, . . . ,
where the parameters r( j) are uniformly distributed random numbers on [0,1], and ηi = −i when the system states lie in
the interior of the positive orthant R6+ . At the boundary of R6+ , the lower bound ηi has to be chosen as the following:
η1 = max{−s1,−1},
η2 = max
{−q1e−u1β1(z1 + T0)z6,−2},
η3 = max
{−q2e−u1β1(z1 + T0)z6 − k1z2,−3},
η4 = max{−s2,−4},
η5 = max
{−qMβ2e−u1(z4 + M0)z6,−5},
η6 = max
{−e−u2 p1z3 − e−u2 p2z5,−6},
to guarantee that the positive orthant R6+ is positively invariant.
A.M. Elaiw, X. Xia / J. Math. Anal. Appl. 359 (2009) 285–301 297Fig. 1. The evolution of uninfected CD4+ T cells under robust MPC for cases (I)–(III).
Fig. 2. The evolution of latently infected CD4+ T cells under robust MPC for cases (I)–(III).
Simulations for the continuous-time system are carried out using ode45 program in MATLAB for three cases:
(I) wi(t) = 0;
(II) 1 = 2000, 2 = 10, 3 = 1, 4 = 100, 5 = 1, 6 = 5;
(III) 1 = 4000, 2 = 20, 3 = 2, 4 = 200, 5 = 2, 6 = 10.
Figs. 1–6 show the evolution of the HIV model variables under the application of multirate MPC strategy for the cases
(I)–(III). Figs. 1 and 4 show that, when the MPC is applied, the number of uninfected CD4+ T cells is increasing as well
as the macrophages but with a slower rate than CD4+ T cells. This means that, the HAART helps the immune system to
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Fig. 4. The evolution of uninfected macrophages under robust MPC for cases (I)–(III).
recover with some ﬂuctuations due to the presence of disturbances. From Fig. 3 and 5, we can see that the number of
latently infected CD4+ T cells, actively infected CD4+ T cells, and infected macrophages are decaying during the treatment.
Fig. 6 shows that, after initiation of HAART, the viral load drops quickly and it can be kept under a suitable level, with
a small controller, corresponding to rather mild dosage of HAART. The model predictive controller as a function of the
time for case (II) is shown in Fig. 7. It is observed that, the treatment is initiated with a stronger dosage of HAART, and
sequentially decreasing over time. Thus we can say that, when the multirate MPC strategy is applied in the presence of
bounded disturbances, the trajectory of the system tends to a ball around the uninfected steady state E0 and remains
there (i.e., practical stability). We observe that, for the disturbance-free (I), the size of the ball is very small due to small
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Fig. 6. The evolution of free viruses under robust MPC for cases (I)–(III).
numerical errors. For cases (II) and (III), the size of the ball becomes larger and larger by increasing the bounds of the
disturbances.
6. Conclusion
The basic properties of the 6-dimensional HIV model incorporating to allow some additive disturbances were studied.
The stabilizing property of multirate MPC for nonlinear systems with additive disturbances via approximate discrete-time
model of the nominal system was proved. Highly Active AntiRetroviral Therapy (HAART) is used. The control input is de-
ﬁned to be dependent on the drug dose and drug eﬃciency. The proposed MPC method is applied for determining HAART
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schedules and stabilizing the HIV system around the uninfected steady state. The results of simulations show that the
proposed method can effectively be applied to eliminate some drawbacks of the approaches previously published in the
literature.
Acknowledgments
The authors are grateful to Prof. E. Gyurkovics (School of Mathematics, Budapest University of Technology and Economics) for her precious ideas and
comments and to the anonymous reviewer for constructive suggestions and valuable comments, which improve the quality of the paper.
References
[1] B.M. Adams, H.T. Banks, M. Davidian, H.-D. Kwon, H.T. Tran, S.N. Wynne, E.S. Rosenberg, HIV dynamics: Modeling, data analysis, and optimal treatment
protocols, J. Comput. Appl. Math. 184 (2005) 10–49.
[2] F. Allgöwer, T.A. Badgwell, J.S. Qin, J.B. Rawlings, S.J. Wright, Nonlinear predictive control and moving horizon estimation-an introductory overview, in:
P.M. Frank (Ed.), Advances in Control, Springer, Berlin, 1999, pp. 391–449.
[3] J. Alvarez-Ramirez, M. Meraz, J.X. Velasco-Hernandez, Feedback control of the chemotherapy of HIV, Int. J. Bifur. Chaos 10 (9) (2000) 2207–2219.
[4] H.T. Banks, H.-D. Kwon, J.A. Toivanen, H.T. Tran, A state-dependent Riccati equation-based estimator approach for HIV feedback control, Optimal Control
Appl. Methods 27 (2006) 93–121.
[5] M.E. Brandt, G. Chen, Feedback control of a biodynamical model of HIV-1, IEEE Trans. Biom. Engrg. 48 (2001) 754–759.
[6] M.A.L. Caetano, T. Yoneyama, Short and long period optimization of drug doses in the treatment of AIDS, An. Acad. Brasil. Cienc. 74 (2002) 589–597.
[7] D.S. Callaway, A.S. Perelson, HIV-1 infection and low steady state viral loads, Bull. Math. Biol. 64 (2002) 29–64.
[8] H. Chen, F. Allgöwer, A quasi-inﬁnite horizon nonlinear model predictive control scheme with guaranteed stability, Automatica 34 (10) (1998) 1205–
1217.
[9] R.V. Culshaw, S. Ruan, R.J. Spiteri, Optimal HIV treatment by maximising immune response, J. Math. Biol. 48 (5) (2004) 545–562.
[10] A.M. Elaiw, Multirate sampling and input-to-state stable receding horizon control for nonlinear sampled-data systems, Nonlinear Anal. 67 (2007)
1637–1648.
[11] A.M. Elaiw, Receding horizon control method applied to antiviral treatment of AIDS, Miskolc Math. Notes 5 (2004) 173–186.
[12] A.M. Elaiw, K. Kiss, M.A.L. Caetano, Stabilization of HIV/AIDS model by receding horizon control, J. Appl. Math. Comput. 18 (1–2) (2005) 95–112.
[13] K.R. Fister, S. Lenhart, J.S. McNally, Optimizing chemotherapy in an HIV model, Electron. J. Differential Equations 1998 (1998) 1–12.
[14] F.A.C.C. Fontes, A general framework to design stabilizing nonlinear model predictive controllers, Systems Control Lett. 42 (2) (2000) 127–143.
[15] É. Gyurkovics, Receding horizon control via Bolza-type optimization, Systems Control Lett. 35 (3) (1998) 195–200.
[16] É. Gyurkovics, A.M. Elaiw, Stabilization of sampled-data nonlinear systems by receding horizon control via discrete-time approximations, Automat-
ica 40 (12) (2004) 2017–2028.
[17] E. Gyurkovics, A.M. Elaiw, A stabilizing sampled-data -step receding horizon control with application to a HIV/AIDS model, Differential Equations
Dynam. Systems 14 (3–4) (2006) 323–352.
[18] E. Gyurkovics, A.M. Elaiw, Conditions for MPC based stabilization of sampled-data nonlinear systems via discrete-time approximations, Lecture Notes
in Control and Inform. Sci. 358 (2007) 35–48.
[19] A.M. Jeffery, X. Xia, I.K. Craig, Structured treatment interruptions: A control mathematical approach to protocol design, J. Process. Control 17 (2007)
571–594.
[20] A.M. Jeffery, A control theoretic approach to HIV/AIDS drug dosage design and timing the initiation of therapy, PhD thesis, department of electrical,
electronic and computer engineering, University of Pretoria, 2006.
[21] A.M. Jeffrey, X. Xia, I.K. Craig, When to initiate HIV therapy: A control theoretic approach, IEEE Trans. Biom. Engrg. 50 (11) (2003) 1213–1220.
A.M. Elaiw, X. Xia / J. Math. Anal. Appl. 359 (2009) 285–301 301[22] A.M. Jeffrey, X. Xia, Identiﬁability of HIV/AIDS models, in: Wai-Yuan Tan, Hulin Wu (Eds.), Deterministic and Stochastic Models of AIDS Epidemics and
HIV Infections with Intervention, World Scientiﬁc Publishing, Singapore, 2005, pp. 255–286.
[23] H.R. Joshi, Optimal control of an HIV immunology model, Optimal Control Appl. Methods 23 (2002) 199–213.
[24] D. Kirschner, S. Lenhart, S. Serbin, Optimal control of the chemotherapy of HIV, J. Math. Biol. 35 (1997) 775–792.
[25] J.H. Ko, W.H. Kim, C.C. Chung, Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability, IEEE Trans.
Biom. Engrg. 53 (3) (2006) 380–386.
[26] A. Korobeinikov, Global properties of basic virus dynamics models, Bull. Math. Biol. 66 (2004) 879–883.
[27] H.-D. Kwon, Optimal treatment strategies derived from a HIV model with drug-resistant mutants, Appl. Math. Comput. 188 (2007) 1193–1204.
[28] U. Ledzewicz, H. Schättler, On optimal controls for a general mathematical model for chemotherapy of HIV, in: Proceedings of American Control
Conference, Denver, 2003, pp. 3454–3459.
[29] D.Q. Mayne, J.B. Rawlings, C.V. Rao, P.O.M. Scokaert, Constrained model predictive control: Stability and optimality, Automatica 36 (6) (2000) 789–814.
[30] D. Nešic´, A.R. Teel, A framework for stabilization of nonlinear sampled-data systems based on their approximate discrete-time models, IEEE Trans.
Automat. Control 49 (7) (2004) 1103–1122.
[31] D. Nešic´, A.R. Teel, P.V. Kokotovic´, Suﬃcient conditions for stabilization of sampled-data nonlinear systems via discrete-time approximation, Systems
Control Lett. 38 (4–5) (1999) 259–270.
[32] D. Nešic´, D.S. Laila, A note on input-to-state stabilization of sampled-data nonlinear systems, IEEE Trans. Automat. Control 47 (7) (2002) 1153–1158.
[33] A.S. Perelson, D. Kirschner, R. De Boer, Dynamic of HIV infection of CD4+ T cells, Math. Biosci. 114 (1) (1993) 81–125.
[34] A.S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, D.D. Ho, Decay characteristics of HIV-1-infected compartments
during combination therapy, Nature 387 (1997) 188–191.
[35] A.S. Perelson, P.W. Nelson, Mathematical analysis of HIV-1 dynamics in vivo, SIAM Rev. 41 (1) (1999) 3–44.
[36] B. Ramratnam, S. Bonhoeffer, J. Binley, A. Hurleyel, et al., Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume
plasma apheresis, Lancet 354 (20) (1999) 1782–1785.
[37] H. Shim, S.J. Han, I.S. Jeong, C.C. Chung, S.W. Nam, J.H. Seo, Optimal scheduling of drug treatment for HIV infection: Continuous dose control and
receding horizon control, Internat. J. Control, Autom. and Systems 1 (2003) 401–407.
[38] B.M. Adams, H.T. Banks, H.-D. Kwon, H.T. Tran, Dynamic multidrug therapies for HIV: Optimal and STI control approaches, Math. Biosci. Eng. 1 (2004)
223–241.
[39] R. Zurakowski, A.R. Teel, A model predictive control based scheduling method for HIV therapy, J. Theoret. Biol. 238 (2006) 368–382.
[40] X. Xia, Estimation of HIV/AIDS parameters, Automatica 39 (2003) 1983–1988.
[41] X. Xia, C.H. Moog, Identiﬁability of nonlinear systems with application to HIV/AIDS models, IEEE Trans. Automat. Control 48 (2003) 330–336.
[42] X. Xia, Modelling of HIV infection: Vaccine readiness, drug effectiveness and therapeutical failures, J. Process. Control 17 (2007) 253–260.
